Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis


NCTID NCT02317887 (View at clinicaltrials.gov)
Description
Indication Retinoschisis, X-Linked
Compound Name RS1 AAV Vector (AAV8-scRS/IRBPhRS)
Sponsor VegaVect, Inc.
Funder Type Industry
Status
Completed
Enrollment Count 12

Therapy Information


Target Gene/Variant RS1
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Intravitreal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV8
Editor Type none
Dose 1 1E9 vg/eye
Dose 2 1E10 vg/eye
Dose 3 1E11 vg/eye
Dose 4 < 3E11 vg/eye
Dose 5 < 6E11 vg/eye

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2014-12-16
Completion Date 2024-10-16
Last Update 2025-02-14

Participation Criteria


Eligible Age >=18 Years
Standard Ages Adult, Older adult
Eligible Sex MALE

Locations


No.of Trial Sites 1
Locations United States

Regulatory Information


Has US IND True
Recent Updates

Resources/Links